|
PTPN6 |
protein tyrosine phosphatase non-receptor type 6 |
- GPVI-mediated activation cascade
- Regulation of KIT signaling
- Signaling by ALK
- PECAM1 interactions
- Co-inhibition by PD-1
- Signal regulatory protein family interactions
- Platelet sensitization by LDL
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- CD22 mediated BCR regulation
- Neutrophil degranulation
- Interferon gamma signaling
- Regulation of IFNG signaling
- Interleukin-37 signaling
- Interferon alpha/beta signaling
- Interleukin receptor SHC signaling
- Regulation of IFNA/IFNB signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Nuclear events stimulated by ALK signaling in cancer
- Growth hormone receptor signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Co-inhibition by BTLA
|
|
|
|
PTPRR |
protein tyrosine phosphatase receptor type R |
|
|
|
|
RASA1 |
RAS p21 protein activator 1 |
- Downstream signal transduction
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- VEGFR2 mediated cell proliferation
- Regulation of RAS by GAPs
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
- RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
|
|
SERPINF1 |
serpin family F member 1 |
|
|
|
|
SH2D2A |
SH2 domain containing 2A |
|
|
|
|
SHB |
SH2 domain containing adaptor protein B |
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
|
|
|
|
SHC1 |
SHC adaptor protein 1 |
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signalling to RAS
- SHC1 events in EGFR signaling
- Tie2 Signaling
- Integrin signaling
- XBP1(S) activates chaperone genes
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- RET signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|
|
SHC2 |
SHC adaptor protein 2 |
- Signalling to RAS
- Signalling to RAS
- VEGFA-VEGFR2 Pathway
- RAF/MAP kinase cascade
|
|
|
|
SHOX2 |
SHOX homeobox 2 |
|
|
|
|
SNCA |
synuclein alpha |
- Amyloid fiber formation
- PKR-mediated signaling
|
- Resveratrol
- Dequalinium
- Copper
|
- Lewy body dementia (LBD); Dementia with Lewy bodies (DLB)
- Parkinson's disease (PD)
|
|
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- RHOU GTPase cycle
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- GPER1 signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- Degradation of CDH1
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric acid
- Paratoulene phosphate
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Tirbanibulin
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- PD-168393
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- PP-121
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
- Fostamatinib
|
|
|
SRP72 |
signal recognition particle 72 |
- SRP-dependent cotranslational protein targeting to membrane
- SRP-dependent cotranslational protein targeting to membrane
|
|
|
|
STAT1 |
signal transducer and activator of transcription 1 |
- Interleukin-6 signaling
- ISG15 antiviral mechanism
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-20 family signaling
- Regulation of RUNX2 expression and activity
- Interleukin-35 Signalling
- Interleukin-9 signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- Interleukin-27 signaling
- Interleukin-21 signaling
- Interferon alpha/beta signaling
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Signaling by ALK fusions and activated point mutants
- Growth hormone receptor signaling
- PKR-mediated signaling
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Regulation of PD-L1(CD274) transcription
|
|
- Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
- IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency
|
|
STYX |
serine/threonine/tyrosine interacting protein |
|
|
|
|
SYNGAP1 |
synaptic Ras GTPase activating protein 1 |
- Regulation of RAS by GAPs
|
|
- Non-syndromic autosomal dominant mental retardation
|
|
TIMP3 |
TIMP metallopeptidase inhibitor 3 |
|
|
|
|
USP7 |
ubiquitin specific peptidase 7 |
- Ub-specific processing proteases
- Formation of TC-NER Pre-Incision Complex
- Transcription-Coupled Nucleotide Excision Repair (TC-NER)
- Dual incision in TC-NER
- Gap-filling DNA repair synthesis and ligation in TC-NER
- Regulation of TP53 Degradation
- Synthesis of active ubiquitin: roles of E1 and E2 enzymes
- Regulation of PTEN localization
|
|
|
|
UTP3 |
UTP3 small subunit processome component |
- rRNA modification in the nucleus and cytosol
- Major pathway of rRNA processing in the nucleolus and cytosol
|
|
|
|
VEGFA |
vascular endothelial growth factor A |
- Platelet degranulation
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by VEGF
- VEGF ligand-receptor interactions
- VEGF binds to VEGFR leading to receptor dimerization
- Interleukin-4 and Interleukin-13 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
|
- Bevacizumab
- Minocycline
- Gliclazide
- Carvedilol
- Ranibizumab
- Pidolic acid
- Pegaptanib
- Vandetanib
- ABT-510
- Veglin
- Denibulin
- SNS-032
- Bevasiranib
- Dalteparin
- Aflibercept
- Chondroitin sulfate
- Foreskin keratinocyte (neonatal)
- Vanucizumab
- Brolucizumab
- Faricimab
|
|
|
VEGFC |
vascular endothelial growth factor C |
- Platelet degranulation
- VEGF ligand-receptor interactions
- VEGF binds to VEGFR leading to receptor dimerization
|
|
|